Revolution Medicines, Inc. $RVMD Position Cut by Candriam S.C.A.

Candriam S.C.A. lowered its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 19.9% in the third quarter, Holdings Channel.com reports. The fund owned 445,693 shares of the company’s stock after selling 110,699 shares during the quarter. Candriam S.C.A.’s holdings in Revolution Medicines were worth $91,817,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Burkett Financial Services LLC purchased a new stake in shares of Revolution Medicines during the 3rd quarter worth $27,000. Contravisory Investment Management Inc. acquired a new position in shares of Revolution Medicines during the 2nd quarter worth $32,000. ABS Investment Management LLC acquired a new position in shares of Revolution Medicines during the 2nd quarter worth $337,104,000. Johnson Financial Group Inc. purchased a new position in shares of Revolution Medicines in the 2nd quarter valued at about $37,000. Finally, Mather Group LLC. purchased a new position in shares of Revolution Medicines in the 3rd quarter valued at about $41,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $192.28 on Friday. The stock has a fifty day moving average price of $196.88 and a 200 day moving average price of $157.56. The stock has a market cap of $41.21 billion, a PE ratio of -21.11 and a beta of 1.44. Revolution Medicines, Inc. has a 1 year low of $58.91 and a 1 year high of $224.31. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.38 and a current ratio of 8.36.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The firm had revenue of $197.56 million for the quarter, compared to analysts’ expectations of $25.58 million. During the same quarter in the previous year, the firm posted ($1.61) earnings per share. Sell-side analysts forecast that Revolution Medicines, Inc. will post -7.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RVMD has been the subject of several recent analyst reports. Truist Financial reiterated a “buy” rating and issued a $261.00 price objective (up from $241.00) on shares of Revolution Medicines in a research note on Thursday. UBS Group boosted their price objective on shares of Revolution Medicines from $220.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, August 28th. HC Wainwright upped their target price on shares of Revolution Medicines from $280.00 to $350.00 and gave the stock a “buy” rating in a research report on Friday. Oppenheimer increased their target price on shares of Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $263.15.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

Insiders Place Their Bets

In related news, Director Elizabeth M. Anderson sold 10,143 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $193.04, for a total value of $1,958,004.72. Following the sale, the director directly owned 4,333 shares in the company, valued at $836,442.32. The trade was a 70.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alan B. Sandler sold 6,309 shares of the business’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total transaction of $1,275,301.26. Following the completion of the sale, the insider owned 52,559 shares in the company, valued at $10,624,276.26. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 290,991 shares of company stock valued at $59,422,765. Company insiders own 7.60% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers.

The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.